NDAOPHTHALMICSOLUTION/DROPS
Approved
May 2003
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
7
Data completeness
6/8 — Strong
ACULAR LS (ketorolac tromethamine) by AbbVie is anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. First approved in 2003.
Drug data last refreshed 13h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACULAR LS is a ketorolac tromethamine ophthalmic solution approved in 2003 for topical ocular use. It is a nonsteroidal anti-inflammatory drug that reduces prostaglandin biosynthesis to provide analgesic, anti-inflammatory, and anti-pyretic activity in the eye. The product treats post-operative ocular inflammation and pain in patients undergoing or recovering from eye surgery.
$0.024BPart D
LOE ApproachingDeclining
1.2 years to LOEAs LOE approaches within 1.2 years, the brand team is likely contracting with focus shifting to generic transition planning and loss mitigation rather than growth initiatives.
Mechanism of Action
anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
Comparison Of Ketorolac Tromethamine Versus Naproxen For Moderate to Severe Back Pain Treatment
Started Mar 2013
83 enrolled
Back Pain
Comparison Of Ketorolac Tromethamine Oral Drops Versus Naproxen For Moderate to Severe Back Pain Treatment
Started Mar 2013
78 enrolled
Back Pain
Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthalmic Solution Compared With Olopatadine Hydrochloride Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis
Started Dec 2010
129 enrolled
Rhinitis, Allergic, SeasonalConjunctivitis, Allergic
A 6 Month Study to Evaluate the Safety, Analgesic Efficacy of ACUVAIL™ (Ketorolac Tromethamine Ophthalmic Solution) 0.45%, in Post-PRK Corneal Wound Healing
Started Aug 2010
10 enrolled
Must be PRK Candidate
Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells
Started May 2007
31 enrolled
Open Angle Glaucoma
Worked on ACULAR LS at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.